Everything seemed on track… until it wasn’t. Germany made history as the European country that went furthest with cannabis regulation, both on the recreational and medical fronts. In no time, record-breaking imports rolled in, the market expanded, and thousands of patients found relief thanks to easier access. Legalizing medical cannabis opened up economic opportunities, but it also meant concrete improvements in quality of life, especially for those who depend on this treatment.
Among those advances came telemedicine: the option to consult with doctors online and get prescriptions without ever having to set foot in a doctor’s office. On top of that, pharmacies handled distribution, sometimes even offering home delivery. For a while, everything seemed to be running smoothly.
But now the Ministry of Health, led by Nina Warken, has hit the brakes. Their official reasoning is this: they fear the system’s flexibility is being abused by recreational users masquerading as patients. Against that backdrop, the government introduced a draft bill to restrict online prescriptions and ban home delivery of cannabis flower. The draft was withdrawn from the cabinet on September 10 and is expected to be reconsidered on October 8, 2025, according to Business of Cannabis.
In-person checkups, or nothing at all
The initiative requires patients to attend in-person appointments at least once every quarter and to pick up their cannabis flower directly from pharmacies, explained Franziska Katterbach, partner at Oppenhoff law firm.
In practice, this would mean the end of online consultations and home delivery, two mechanisms that had expanded access to treatment, especially for people living in rural areas or those with limited mobility.
The Health Ministry is, basically, pushing for less reliance on digital platforms and stronger in-person relationships between doctors and patients. Critics, however, warn that this would especially harm the very groups mentioned above, since they’d lose a channel that ensured continuity of care without costly—or travel that is physically impossible. That being said, they claim that, instead of killing telemedicine altogether, the government should keep it alive but tighten oversight.
Several experts argue the bill ignores the fact that safeguards against abuse are already in place. As Katterbach pointed out, current law already bans automated prescription systems without physician oversight, minimizing abuse risks. In other words, the existing legal framework already blocks bots or algorithms from prescribing cannabis without professional supervision. So why ban it altogether instead of just tightening controls?
Opponents argue this measure isn’t evidence-based, but rather a step backward fueled by political suspicion. Sure, import numbers have gone up, but that doesn’t necessarily imply telemedicine is being massively exploited by recreational users.
Legal tensions: What about European law?
Meanwhile, EU law guarantees doctors the right to practice freely, patients the right to access treatment, and services the right to circulate without barriers across member states. If Germany tightens the screws too much, those guarantees could come into direct conflict with the new restrictions.
This shows how the debate has gone beyond health policy, moving to the legal arena. Several experts warn that the bill could undermine basic principles of European law. Besides, it would also limit the professional autonomy of German doctors, forcing them into stricter conditions than their colleagues elsewhere in the EU.
Katterbach explains that this move could run counter to the principles of the EU single market and the freedom to provide services under Article 56 of the Treaty on the Functioning of the European Union. She also warned that such restrictions would only be valid if justified by an overriding public interest; something that, in this case, doesn’t apply.
The problem is easy to spot. If Germany clamps down on telemedicine for its own doctors, patients could simply turn to neighboring EU countries where the practice remains legal. Those prescriptions would still be valid in German pharmacies, putting local physicians at a disadvantage compared to their foreign peers.
Germany, don’t let us down
In the end, the measure looks more like a step backward—based on suspicion and shaky assumptions, with little evidence to back them up—than an effective response to the regulatory challenges of medical cannabis. Katterbach herself summed it up clearly: “Telemedicine should be promoted as a modern model of care, not restricted.”
Germany stunned the world with its pioneering regulation, but now risks losing credibility with both patients and professionals. The key isn’t prohibition, but trust: stronger documentation, audits, or even a voluntary industry code of conduct could help strike a balance between oversight and access.
